fbpx
close read more
News

Oncology: discover our partnership with Vernalis in video

24/02/2022

Oncology: discover our partnership with Vernalis in video

Servier favors open collaboration to accelerate the development of therapeutic solutions for the benefit of patients. Here is a video example of our partnership with the biotech Vernalis to advance research in oncology.

https://www.youtube.com/watch?v=rXivXBpJII4

 

Convinced that work and ongoing dialogue between healthcare players is the best framework for rapid innovation focused on patients’ needs, Servier continues to expand and diversify its network of R&D partners.

This international and multidisciplinary network is made up of academic institutions, pharmaceutical groups and biotech companies. All of them are committed to Servier for the long term.

The partnership between Vernalis Research and Servier has been running since 2007 with several collaborations on different therapeutic targets.

In 2020, Vernalis Research and Servier expanded their collaboration in oncology with a new three-year research partnership that combines Vernalis’ structural biology strengths with Servier’s oncology expertise.

In 2021, the companies announced the achievement of 2 key steps in new drug development: a preclinical milestone and a research milestone. Read more

Did you know?

There are currently 40 Servier R&D projects in oncology (January 2022)

Last news

News
29/09/2022
World Heart Day: Servier partner of the World Heart Federation campaign!
News
26/09/2022
Parkinson: Servier exercises the exclusive licensing option on collaborative program with Oncodesign Precision Medicine
News
22/09/2022
Servier collaborates in the treatment of pancreatic cancer